We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2%
Spectrum Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares jump a little above 22% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $7.28 to $8.25 in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved lower over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Spectrum currently carries a Zacks Rank #3 (Hold).
Spectrum Pharmaceuticals, Inc. Price
Spectrum Pharmaceuticals, Inc. Price | Spectrum Pharmaceuticals, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is Aerie Pharmaceuticals, Inc. , which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is SPPI going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>